Biomnis

Sainte-Foy-lès-Lyon, France
Sainte-Foy-lès-Lyon, France
SEARCH FILTERS
Time filter
Source Type

Shahali Y.,ESPCI ParisTech | Sutra J.-P.,ESPCI ParisTech | Mari A.,Center for Molecular Allergology | Guilloux L.,Biomnis | And 4 more authors.
FEBS Journal | Year: 2012

The common cypress (Cupressus sempervirens) (Cups) pollen represents the first cause of respiratory allergies in the Mediterranean basin. The aim of this study was to characterize a novel 14-kDa cypress pollen allergen (BP14) allowing a clear dissociation of IgE sensitization patterns among allergic patients. The biochemical and immunochemical characterization of BP14 included determination of its isoelectric point, molecular mass, extraction kinetics, IgE binding prevalence, the presence of bromelain-type cross-reactive carbohydrate determinant and its IgE reactivity under reducing conditions. The presence of potential cross-reactive homologues in closely related cypress species, i.e. Cupressus arizonica (Cupa) and Cryptomeria japonica (Cryj), as well as in several taxonomically unrelated species was also investigated. According to our results, BP14 is easily and quickly solubilized in phosphate-buffered saline and exhibits several allergenic isoforms covering a broad range of pI (6.5-10.5). This allergen displays heat-stable conformational epitopes and does not include cross-reactive carbohydrate determinants, in contrast to high molecular weight cypress allergens. BP14 is expressed at higher levels in Cups than in Cupa and Cryj. No IgE cross-reactivity was found between the 14-kDa Cups pollen protein and proteins from some other non-Cupressaceae pollen allergenic sources such as orchard, timothy, wheat, maize, birch, ash and pine. Thus, IgE reactivity to BP14 is specific to Cupressaceae and discriminates two groups of patients allergic to cypress pollen. It might correspond to a relevant marker in relation to the sensitization process and/or the symptoms observed in some cypress-pollen-allergic patients. Furthermore, the description of BP14 should improve the diagnosis of cypress pollinosis. © 2012 The Authors Journal compilation © 2012 FEBS.


Mace G.,University of Burgundy | Feyeux C.,University of Burgundy | Mollard N.,Institute Pasteur Paris | Chantegret C.,University of Burgundy | And 7 more authors.
Eurosurveillance | Year: 2013

We report the first detection of Seoul virus (SEOV) in humans in Europe, causing severe disease in a pregnant woman in France in October 2012. The patient's laboratory test results mimicked that of pregnancy-induced liver pathologies such as acute fatty liver of pregnancy (AFLP) with severe renal failure. This led to an emergency delivery (at 27 weeks' gestation). On the basis of gene S (small) sequence analysis, the Seoul hantavirus strain detected was found to belong to the main SEOV phylogroup.


News Article | October 28, 2016
Site: www.prweb.com

Esker, a worldwide leader in document process automation solutions and pioneer in cloud computing, today announced its participation at LogiMed, Europe’s annual forum for supply chain leaders from top medical device manufacturers, being held Oct. 17-18 in Berlin, Germany. Esker’s customer, St. Jude Medical, a leading global medical device manufacturer, will be present alongside Esker at Stand #4 to discuss how automating its order management process has led to supply chain savings and improved customer service. Order management and supply chain functions are particularly critical in the medical device and pharmaceutical industry in terms of health impacts and patient care. Numerous prominent companies in these sectors have chosen Esker’s order processing solution to automate order management, including: BASF, Bayer, Biomet, Biomnis, Fresenius Medical Care, GE Healthcare, Kern Pharma, Johnson & Johnson, Menarini, Novartis, Philips Respironics, Roche Italia, Sanofi, Siemens, Systagenix and Terumo. Esker enables these companies to optimize their supply chain by helping to meet Service Level Agreements (SLAs). Additionally, with many of their customers in the public sector, these companies are, or will soon be, affected by the European directive on mandatory e-invoicing, and are turning to document process automation solutions for their customer invoices and sales orders. Esker automates thousands of orders received by customers on a daily basis from hospitals, clinics, doctors or other healthcare professionals. These customers have seen a number of significant business benefits thanks to order processing automation, including: “Tighter regulations, expired patents and the growth of generic drugs are some of the many constraints that companies are facing in this industry at a time when they need to cut costs without compromising on the level of service offered to the patients,” said Emmanuel Olivier, chief operating officer of Esker. “Automating business document processes, and particularly purchase orders, helps companies reduce their costs.” St. Jude Medical Customer Testimonial Peter-Paul Van Heesewijk, vice president of worldwide customer service at St Jude Medical, will deliver a master class at LogiMed entitled “Pursuing the Perfect Order: How Can Automation Drive Supply Chain Savings and Customer Excellence?” on Oct. 17 at 12:40 p.m. St. Jude Medical selected Esker for its ability to manage projects on an international scale and automate the order-to-invoice process in its entirety — from order reception to customer invoice processing. As of today, Esker has automated over a million annual customer orders for St. Jude Medical. About Esker Esker is a worldwide leader in cloud-based document process automation software. Esker solutions help organizations of all sizes to improve efficiencies, accuracy, visibility and costs associated with business processes. Esker provides on-demand and on-premises software to automate accounts payable, order processing, accounts receivable, purchasing and more. Founded in 1985, Esker operates in North America, Latin America, Europe and Asia Pacific with global headquarters in Lyon, France and U.S. headquarters in Madison, Wisconsin. Last year Esker generated 58.5 million euros in total sales revenue. For more information on Esker and its solutions, visit http://www.esker.com. Follow Esker on Twitter @EskerInc and join the conversation on the Esker blog at blog.esker.com.


Abramowitz L.,APHP | Jacquard A.-C.,Sanofi S.A. | Jaroud F.,Sanofi S.A. | Haesebaert J.,Sanofi S.A. | And 13 more authors.
International Journal of Cancer | Year: 2011

Anal cancer is a rare cancer but its incidence is increasing. Human papillomavirus (HPV) infection seems to be associated with the occurrence of most cases. The genotype-specific prevalence of HPV in anal cancer was estimated to assess the potential benefit of HPV vaccination in France. Anal cancer histological specimens were retrospectively recruited in 2008 from 16 French centres and centrally tested for HPV genotyping using the INNO-LiPA assay allowing the detection of 28 genotypes. Results were analyzed according to age, gender, HIV status when available and histological diagnosis. A total of 366 anal cancer cases were analyzed among which 62% were females. Mean age at diagnosis was 54.8 years in males and 66.4 years in females (p <0.001). HPV was found in 96.7% of cases, 72% being infected by a single HPV type. Presence of at least one high-risk genotype was observed in 91% of cases (96% in females and 83% in males; p <0.001). HPV16 was by far the most prevalent genotype (75%), followed by HPV18, HPV52, HPV33, and HPV51 (4-6%). HPV16/18 alone or in association were found in 78% of all cases. HIV-positive cases had a higher proportion of multiple HPV infection than HIV-negative cases and a slightly different HPV type distribution with an under-representation of HPV16 and an over-representation of other types. Our results indicate that anal cancer rarely occurs in the absence of HPV and emphasize the predominant role of HPV16. The potential benefit of HPV vaccine on the occurrence of anal cancer should be further evaluated. © 2010 UICC.


PubMed | Biomnis, Abbott Laboratories and Virologie AP HP Hopital Paul Brousse
Type: Journal Article | Journal: Journal of clinical microbiology | Year: 2016

Hepatitis C virus (HCV) genotyping continues to be relevant for therapeutic strategies. Some samples are reported as genotype 1 (gt 1) without subtype by the Abbott RealTime HCV Genotype II (GT II) test. To characterize such samples further, the Abbott HCV Genotype Plus RUO (Plus) assay, which targets the core region for gt 1a, gt 1b, and gt 6 detection, was evaluated as a reflex test in reference to NS5B or 5-untranslated region (UTR)/core region sequencing. Of 3,626 routine samples, results of gt 1 without subtype were received for 171 samples (4.7%), accounting for 11.5% of gt 1 specimens. The Plus assay and sequencing were applied to 98 of those samples. NS5B or 5-UTR/core region sequencing was successful for 91/98 specimens (92.9%). Plus assay and sequencing results were concordant for 87.9% of specimens (80/91 samples). Sequencing confirmed Plus assay results for 82.6%, 85.7%, 100%, and 89.3% of gt 1a, gt 1b, gt 6, and non-gt 1a/1b/6 results, respectively. Notably, 12 gt 6 samples that had been identified previously as gt 1 without subtype were assigned correctly here; for 25/28 samples reported as not detected by the Plus assay, sequencing identified the samples as gt 1 with subtypes other than 1a/1b. The genetic variability of HCV continues to present challenges for the current genotyping platforms regardless of the applied methodology. Samples identified by the GT II assay as gt 1 without subtype can be further resolved and reliably characterized by the new Plus assay.


Shahali Y.,ESPCI ParisTech | Sutra J.-P.,ESPCI ParisTech | Haddad I.,ESPCI ParisTech | Vinh J.,ESPCI ParisTech | And 6 more authors.
Electrophoresis | Year: 2012

Italian cypress (Cupressus sempervirens, Cups) pollen causes allergic diseases in inhabitants of many of the cities surrounding the Mediterranean basin. However, allergens of Cups pollen are still poorly known. We introduce here a novel proteomic approach based on double one-dimensional gel electrophoresis (D1-DE) as an alternative to the 2-DE immunoblot, for the specific IgE screening of allergenic proteins from pollen extracts. The sequential one-dimensional combination of IEF and SDS-PAGE associated with IgE immunoblotting allows a versatile multiplexed immunochemical analysis of selected groups of allergens by converting a single protein spot into an extended protein band. Moreover, the method appears to be valuable for MS/MS identification, without protein purification, of a new Cups pollen allergen at 43kDa. D1-DE immunoblotting revealed that the prevalence of IgE sensitization to this allergen belonging to the polygalacturonase (PG) family was 70% in tested French allergic patients. In subsequent triple one-dimensional gel electrophoresis, the Cups pollen PG was shown to promote lectin-based protein-protein interactions. Therefore, D1-DE could be used in routine work as a convenient alternative to 2-DE immunoblotting for the simultaneous screening of allergenic components under identical experimental conditions, thereby saving considerable amounts of sera and allergen extracts. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.


Thibaudon M.,RNSA | Hamberger C.,Biomnis | Guilloux L.,Biomnis | Massot R.,RNSA
European Annals of Allergy and Clinical Immunology | Year: 2010

Purpose of the study: To detect the origin of ragweed pollen and to measure the impact of this pollen exposure on allergic patients, so their sensitivity can be noted (using specific IgE production: sIgEw1) in order to inform the population about an allergy against those ragweed pollen grains. Material and methods: To measure population exposure to ragweed pollen, the R.N.SA (NationalAerobiological Monitoring Network, a French association) has a pollen trap network located in urban areas. These traps allow continuous recording of airborne pollen, the light microscope analysis (with a bi-hourly time step) allows one to know the daily concentrations of ragweed grains and the circadian rhythm of grains impaction. It is thus possible to follow the evolution of pollination during each day of each season and to compare seasons and years at each station. Biomnis is a biological Laboratory which performs more than 85% of ragweed specific IgE assay in France. It seems to be clear that when allergists ask ragweed IgE for a patient, it is because they think that this patient seems to be allergic to this specific pollen. The statistical analysis of results about specific IgE (for ragweed) from the Allergology laboratories Biomnis (located in Lyon and Paris) can determine the number of patients sensitized to ragweed in French departments. Results: The distribution of sensitized patients to ragweed is compared to ragweed pollen distribution studied by the R.N.S A from the year 2005 to 2008 in France, whatever the ragweed plant origin: local (closed to pollen trap) or imported (by wind). Conclusion: The biological database (Health impact) allows a correlation between the geographical distribution of ragweed pollen and the number of patients with specific IgE against ragweed (sIgEw1), i.e whose sensitization is due to local plants. That also permits one to estimate the expected number of allergy cases in the next years, because the sensitivity precedes the allergy.


Samama M.M.,Biomnis | Kunitada S.,Daiichi Sankyo | Oursin A.,Biomnis | Depasse F.,Biomnis | Heptinstall S.,University of Nottingham
Thrombosis Research | Year: 2010

Introduction: Edoxaban (the free base of DU-176b) is a new, oral direct Factor Xa inhibitor. This is the first study to compare the hemostatic response to edoxaban, ximelagatran, and dalteparin in healthy, elderly adults. Materials and Methods: In this open-label, active-controlled clinical trial, 40 adults (65-75 years), were randomised to: oral edoxaban (60 mg, twice-daily, 7 doses), subcutaneous dalteparin (5000 IU, once-daily, 4 doses), oral ximelagatran (24 mg, twice-daily, 7 doses) or no drug. Blood samples were taken before, and 1.5, 4, 12, 24, 72, 84, 96, 108, 120, and 144 hours after, the first dose. The primary outcomes were changes in thrombin-antithrombin complex, prothrombin fragment 1 + 2 and D-dimer, and adverse events. Additional biomarkers of coagulation, and endothelial cell and platelet activation were compared (ANOVA). Results: All subjects completed the study. Inhibition of thrombin generation lag time, peak, and constant velocity index were significantly greater, and extended for a longer period of time, following edoxaban administration, compared with dalteparin. We found that the traditional assay for anti-FXa activity was not appropriate for the new anticoagulants. Biomarker changes following edoxaban administration (including prolongation of prothrombin time) reflected inhibition of Factor Xa; there was no effect on platelet, tissue factor or endothelial activation. There were no clinically significant changes in primary outcomes. No serious adverse events were reported. Conclusion: Oral administration of edoxaban resulted in effective Factor Xa and TG inhibition, and was well-tolerated. Studies are needed to confirm edoxaban (60 mg daily) use in clinical practice. Sponsorship: Daiichi Sankyo Pharma Development. © 2009 Elsevier B.V.


PubMed | BIOMNIS, Institute medical danalyse genomique and Montpellier University Hospital Center
Type: Journal Article | Journal: Annales de biologie clinique | Year: 2016

Insulin-antibodies are a cause of misleading results in insulin immunoassays. They may also mediate deleterious blood glucose variations. A patient presented with overtiredness, recurrent episodes of sweating, dizziness and fainting fits. A fasting serum insulin assay performed on a Modular platform (Modular analytic E170, Roche Diagnostic, Meylan, France) showed a highly elevated value of 194.7 mIU/L, whereas on the same sample glucose and C-peptide levels were normal. Other immunometric insulin assays were performed, as well as antibodies anti-insulin radiobinding assay (RBA) and gel filtration chromatography (GFC). While complementary insulin assays yielded closer to normal fasting levels, the free insulin concentration assessed after PEG precipitation was 14.0 mIU/L and the RBA was positive. GFC revealed that most of the insulin was complexed with a 150kDa molecule, corresponding to an immunoglobulin G (IgG). A high fasting serum insulin level in a patient with neuroglucopenic symptoms was related to a high insulin-antibody level, suggesting an insulin autoimmune syndrome.


Guilloux L.,Biomnis
Revue Francaise d'Allergologie | Year: 2010

Allergy is in constant progression in industrialized countries, where it affects almost one out of five people and changes the quality of life of those who suffer from it. These hypersensitivity conditions require early diagnosis which, in addition to the initial care of the illness, allows its evolution to be anticipated. Studies on the quantitative value of specific serum IgE have allowed us to associate such data with the likelihood of a clinical reaction or to establish the probable evolution of the disease. Recent progress in molecular biology, which has led to the synthesis of individual allergenic components (native and recombinant), has provided a real turning point for allergy diagnosis. With these molecules, it is now possible to establish for each patient a spectrum of IgE sensitivities, which can be associated with prognostic factors in terms of severity and/or persistence of the allergic disease. © 2010 Elsevier Masson SAS. All rights reserved.

Loading Biomnis collaborators
Loading Biomnis collaborators